The Operational Vital Signs
Key metrics on the metabolic health of cdl drivers.
69%
Obesity Rate
CDL drivers have an obesity rate of 69% — more than double the 31% national average.
52.4%
Metabolic Syndrome
52.4% prevalence of metabolic syndrome among CDL drivers — 2.7× the national rate.
61 Years
Average Life Expectancy
The average CDL driver lives to 61 — 18 years below the national average.
38%+
Without a Primary Care Provider
Over 38% of CDL drivers are uninsured or have no established primary care relationship.
The Threat Matrix
The Metabolic Profile
The Reality: Commercial drivers have an obesity rate more than double the national average and metabolic syndrome prevalence of 52.4%.
The Impact: The occupational conditions of long-haul driving — sedentary time, irregular meals, disrupted sleep, and stress — create a physiological environment that promotes weight gain and insulin resistance.
The Reality: The average CDL driver life expectancy is 61 years — 18 years below the national average.
The Impact: Cardiovascular disease, type 2 diabetes, and sleep apnea are the primary drivers of that gap. All three are addressable through clinical metabolic intervention.
The DOT Certification Risk
The Reality: BMI ≥ 35 triggers mandatory sleep apnea evaluation. Blood pressure ≥ 180/110 mmHg is disqualifying without treatment.
The Impact: GLP-1 therapy produces measurable improvements in blood pressure (4–6 mmHg reduction) and sleep apnea severity — directly affecting DOT certificate eligibility.
The Reality: Tirzepatide has a nausea rate of 24–33% vs. 43.9% with Semaglutide — and roughly half the vomiting rate.
The Impact: For drivers operating a commercial motor vehicle, this distinction is clinically relevant. GI side effects that impair alertness create a safety issue on the road.
Pricing — All-Inclusive
Medication · Supplies · Shipping · Clinical Oversight. One flat price per medication — covers every dose. No hidden fees.
The Tactical Advantage: GLP-1 Therapy
Why Tirzepatide is the first-line choice for active CDL holders — efficacy, tolerability, and DOT relevance.
Blood Pressure Control
4–6 mmHg reduction — directly affecting DOT medical certificate eligibility near the 180/110 threshold.
Diabetes Prevention
94% reduction in progression to type 2 diabetes with Tirzepatide — protecting long-term CDL qualification.
Sleep Apnea Improvement
39% reduction in apnea-hypopnea index at 15% body weight loss — addressing the most common DOT disqualifying condition.